Northwestern Mutual Investment Management Company LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV) by 13.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 279,913 shares of the company’s stock after selling 42,286 shares during the quarter. Northwestern Mutual Investment Management Company LLC’s holdings in AbbVie were worth $17,329,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the business. MCF Advisors LLC boosted its stake in shares of AbbVie by 15.3% in the first quarter. MCF Advisors LLC now owns 4,556 shares of the company’s stock worth $297,000 after buying an additional 606 shares during the last quarter. Greatmark Investment Partners Inc. boosted its stake in shares of AbbVie by 1.7% in the first quarter. Greatmark Investment Partners Inc. now owns 33,936 shares of the company’s stock worth $2,211,000 after buying an additional 560 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its position in AbbVie by 33.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 461,768 shares of the company’s stock worth $30,441,000 after purchasing an additional 115,550 shares in the last quarter. Community Bank N.A. boosted its position in AbbVie by 1.6% during the first quarter. Community Bank N.A. now owns 66,262 shares of the company’s stock worth $4,317,000 after purchasing an additional 1,015 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV boosted its position in AbbVie by 16.8% during the first quarter. Massmutual Trust Co. FSB ADV now owns 98,704 shares of the company’s stock worth $6,432,000 after purchasing an additional 14,194 shares in the last quarter. Institutional investors and hedge funds own 69.32% of the company’s stock.
ABBV has been the topic of a number of recent analyst reports. BidaskClub upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 6th. Evercore ISI reiterated an “outperform” rating and set a $100.00 price target (up previously from $95.00) on shares of AbbVie in a research report on Saturday, September 30th. Societe Generale increased their price target on AbbVie in a research report on Tuesday, November 21st. Barclays reiterated a “hold” rating and set a $68.00 price target on shares of AbbVie in a research report on Thursday, September 28th. Finally, ValuEngine downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Friday. Seven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. AbbVie currently has an average rating of “Buy” and a consensus target price of $96.72.
AbbVie Inc. (NYSE ABBV) opened at $95.22 on Tuesday. AbbVie Inc. has a fifty-two week low of $58.80 and a fifty-two week high of $98.52. The company has a market capitalization of $153,768.13, a P/E ratio of 18.14, a price-to-earnings-growth ratio of 1.36 and a beta of 1.52. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.
AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The firm had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. During the same quarter last year, the firm earned $1.21 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. equities research analysts expect that AbbVie Inc. will post 5.55 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio (DPR) is currently 62.29%.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
What are top analysts saying about AbbVie Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AbbVie Inc. and related companies.